F, Burchard G-D, Andriano K, Lef re G, De Palacios PI

F, Burchard G-D, Andriano K, Lef re G, De Palacios PI, Genton B: Therapy of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg 2008, 78:24147. Osei-Akoto A, Orton L, Owusu-Ofori SP: Atovaquone-proguanil for treating uncomplicated malaria. Cochrane Database Syst Rev 2005, 19(4):CD004529. Giao PT, De Vries PJ, Hung LQ, Binh TQ, Nam NV, Kager PA: CV8, a brand new mixture of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam. Trop Med Int Overall health 2004, 9:20916. Makanga M, Krudsood S: The clinical efficacy of artemether/lumefantrine (Coartem). Malar J 2009, eight(1):S5. Parola P, Ranque S, Badiaga S, Niang M, Blin O, Charbit JJ, Delmont J, Brouqui P: Controlled trial of 3-day quinine-clindamycin remedy versus 7-day quinine34.35.36.37.38.39.40. 41.42. 43.44.therapy for adult travelers with uncomplicated falciparum malaria imported in the tropics. Antimicrob Agents Chemother 2001, 45:93235. Durand R, Prendki V, Cailhol J, Hubert V, Ralaimazava P, Massias L, Bouchaud O, Le Bras J: Plasmodium falciparum malaria and atovaquone-proguanil therapy failure. Emerg Infect Dis 2008, 14:32022. Miura T, Kimura M, Koibuchi T, Endo T, Nakamura H, Odawara T, Wataya Y, Nakamura T, Iwamoto A: Clinical traits of imported malaria in Japan: analysis at a referral hospital. Am J Trop Med Hyg 2005, 73:59903. Hartjes LB, Baumann LC, Henriques JB: Travel overall health risk perceptions and prevention behaviors of US study abroad students. J Travel Med 2009, 16:33843. Rutebemberwa E, Nsabagasani X, Pariyo G, Tomson G, Peterson S, Kallander K: Use of drugs, perceived drug efficacy and preferred providers for febrile children: implications for household management of fever. Malar J 2009, 8:131. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ: Population pharmacokinetics of atovaquone in sufferers with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther 1997, 61:51830. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB: Malarone (atovaquone and proguanil hydrochloride): a critique of its clinical improvement for therapy of malaria: malarone clinical trials study group. Am J Trop Med Hyg 1999, 60:53341. McKeage K, Scott L: Atovaquone/proguanil: a critique of its use for the prophylaxis of Plasmodium falciparum malaria. Drugs 2003, 63:59723. Boggild AK, Parise ME, Lewis LS, Kain KC: Atovaquone-proguanil: report in the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg 2007, 76:20823. Menendez C, Fleming AF, Alonso PL: Malaria-related Anaemia. Parasitol Nowadays 2000, 16:46976. Price RN, Simpson JA, Nosten F, Luxemburger C, Hkirjaroen L, Ter Kuile F, Chongsuphajaisiddhi T, White NJ: Aspects contributing to anemia just after uncomplicated falciparum malaria.Clotrimazole Am J Trop Med Hyg 2001, 65:61422.Lincomycin hydrochloride monohydrate Evaluation of the riametversus malaronein the treatment of uncomplicated malaria – complete text view – clinicaltrials.PMID:23522542 gov. http://clinicaltrials.gov/ct2/show/ NCT01150344.doi:ten.1186/1475-2875-12-399 Cite this short article as: Cordel et al.: Atovaquone-proguanil in the therapy of imported uncomplicated Plasmodium falciparum malaria: a potential observational study of 553 cases. Malaria Journal 2013 12:399.Submit your next manuscript to BioMed Central and take complete advantage of:Handy on the net submission Thorough peer review No space constraints or color figure charges Immed.